These observations lead to the question whether the observed crosstalk between DOT1L and HDAC1 in mouse T cells plays a role in the therapeutic effect of pan-HDAC inhibition in human CTCL. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.